New directions in the pharmacologic treatment of insomnia

Research output: Contribution to journalArticle

Abstract

This article reviews the recently Food and Drug Administration-approved sleep-promoting medications as well as new compounds being investigated as possible future insomnia treatments. The new medications indicated for the treatment of insomnia include significant advances in pharmacokinetic and pharmacodynamic approaches. All approved sleep-promoting medications are indicated for difficulties with sleep onset and some have an additional indication for sleep maintenance. The recently approved insomnia medications no longer have an implied restriction on their duration of use. There is now a controlled-release formulation of a benzodiazepine receptor agonist, as well as a selective melatonin receptor agonist. New potential pharmacologic targets for treating insomnia have become evident, with advances in the understanding of the neural mechanisms regulating the sleep-wake cycle. Currently being evaluated are a wide range of compounds that modulate γ-aminobutyric acid, histamine, serotonin, melatonin, adenosine, corticotrophin-releasing factor, and hypocretin/orexin systems.

Original languageEnglish (US)
Pages (from-to)51-57
Number of pages7
JournalPrimary Psychiatry
Volume13
Issue number8
StatePublished - Aug 2006

Fingerprint

Sleep Initiation and Maintenance Disorders
Sleep
Melatonin Receptors
Aminobutyrates
Therapeutics
Corticotropin-Releasing Hormone
GABA-A Receptors
Melatonin
United States Food and Drug Administration
Adenosine
Histamine
Serotonin
Pharmacokinetics
Maintenance
Direction compound

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Genetics

Cite this

New directions in the pharmacologic treatment of insomnia. / Neubauer, David.

In: Primary Psychiatry, Vol. 13, No. 8, 08.2006, p. 51-57.

Research output: Contribution to journalArticle

@article{0786ba26e43741e78cae6b33830a512f,
title = "New directions in the pharmacologic treatment of insomnia",
abstract = "This article reviews the recently Food and Drug Administration-approved sleep-promoting medications as well as new compounds being investigated as possible future insomnia treatments. The new medications indicated for the treatment of insomnia include significant advances in pharmacokinetic and pharmacodynamic approaches. All approved sleep-promoting medications are indicated for difficulties with sleep onset and some have an additional indication for sleep maintenance. The recently approved insomnia medications no longer have an implied restriction on their duration of use. There is now a controlled-release formulation of a benzodiazepine receptor agonist, as well as a selective melatonin receptor agonist. New potential pharmacologic targets for treating insomnia have become evident, with advances in the understanding of the neural mechanisms regulating the sleep-wake cycle. Currently being evaluated are a wide range of compounds that modulate γ-aminobutyric acid, histamine, serotonin, melatonin, adenosine, corticotrophin-releasing factor, and hypocretin/orexin systems.",
author = "David Neubauer",
year = "2006",
month = "8",
language = "English (US)",
volume = "13",
pages = "51--57",
journal = "Primary Psychiatry",
issn = "1082-6319",
publisher = "MBL Communications",
number = "8",

}

TY - JOUR

T1 - New directions in the pharmacologic treatment of insomnia

AU - Neubauer, David

PY - 2006/8

Y1 - 2006/8

N2 - This article reviews the recently Food and Drug Administration-approved sleep-promoting medications as well as new compounds being investigated as possible future insomnia treatments. The new medications indicated for the treatment of insomnia include significant advances in pharmacokinetic and pharmacodynamic approaches. All approved sleep-promoting medications are indicated for difficulties with sleep onset and some have an additional indication for sleep maintenance. The recently approved insomnia medications no longer have an implied restriction on their duration of use. There is now a controlled-release formulation of a benzodiazepine receptor agonist, as well as a selective melatonin receptor agonist. New potential pharmacologic targets for treating insomnia have become evident, with advances in the understanding of the neural mechanisms regulating the sleep-wake cycle. Currently being evaluated are a wide range of compounds that modulate γ-aminobutyric acid, histamine, serotonin, melatonin, adenosine, corticotrophin-releasing factor, and hypocretin/orexin systems.

AB - This article reviews the recently Food and Drug Administration-approved sleep-promoting medications as well as new compounds being investigated as possible future insomnia treatments. The new medications indicated for the treatment of insomnia include significant advances in pharmacokinetic and pharmacodynamic approaches. All approved sleep-promoting medications are indicated for difficulties with sleep onset and some have an additional indication for sleep maintenance. The recently approved insomnia medications no longer have an implied restriction on their duration of use. There is now a controlled-release formulation of a benzodiazepine receptor agonist, as well as a selective melatonin receptor agonist. New potential pharmacologic targets for treating insomnia have become evident, with advances in the understanding of the neural mechanisms regulating the sleep-wake cycle. Currently being evaluated are a wide range of compounds that modulate γ-aminobutyric acid, histamine, serotonin, melatonin, adenosine, corticotrophin-releasing factor, and hypocretin/orexin systems.

UR - http://www.scopus.com/inward/record.url?scp=33747591926&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33747591926&partnerID=8YFLogxK

M3 - Article

VL - 13

SP - 51

EP - 57

JO - Primary Psychiatry

JF - Primary Psychiatry

SN - 1082-6319

IS - 8

ER -